The AIP Avanos acquisition marks one of the notable private equity transactions in the medical technology sector this year, positioning Avanos Medical for long-term operational expansion under private ownership.
The AIP Avanos acquisition has officially closed, completing a transaction valued at approximately $1.272 billion and bringing Avanos Medical into the portfolio of American Industrial Partners (AIP). With the deal finalized, Avanos has transitioned from a publicly traded company to a privately held business, ending its listing on the New York Stock Exchange and opening a new chapter focused on operational growth, product innovation, and long-term value creation.
Under the terms of the merger agreement, Avanos shareholders will receive $25.00 in cash for each outstanding common share, concluding months of acquisition proceedings. The transaction reflects continued investor interest in established medical technology companies with diversified product portfolios and strong positions in specialized healthcare markets.
The completion of the AIP Avanos acquisition comes at a time when private equity firms are increasingly targeting healthcare and medical technology businesses that demonstrate resilient demand, recurring revenues, and opportunities for operational improvements. Rather than focusing solely on financial restructuring, investors are placing greater emphasis on accelerating innovation, expanding commercial capabilities, and improving manufacturing efficiency to create sustainable long-term growth.
American Industrial Partners, which manages approximately $17.8 billion in assets, has built its investment strategy around acquiring industrial and technology-driven businesses where operational expertise can create measurable improvements. By bringing Avanos into its portfolio, the firm gains a medical technology platform with an established global presence and products addressing critical areas of patient care, including pain management, digestive health, and enteral feeding.
The acquisition also signals confidence in the long-term outlook for the medical technology industry, where demand continues to be supported by aging populations, rising surgical procedures, and increasing healthcare investment across developed and emerging markets.
AIP Avanos Acquisition Supports Long-Term Growth Strategy in Medical Technology
The completion of the AIP Avanos acquisition represents more than a change in ownership. It reflects a strategic move designed to strengthen Avanos’ ability to invest in innovation while operating outside the short-term expectations often associated with public markets.
Private ownership provides companies with greater flexibility to pursue long-term business initiatives without the pressure of quarterly earnings performance. For medical technology companies, where product development, regulatory approvals, and commercialization often require multi-year investment cycles, this operating environment can support more consistent execution.
Avanos has established its business around developing medical devices that address some of healthcare’s most persistent clinical challenges. Its portfolio includes products that support enteral nutrition for patients requiring long-term feeding solutions while also offering technologies designed to help reduce opioid use in pain management and improve post-surgical recovery.
These therapeutic areas continue to receive growing attention from healthcare providers as hospitals seek solutions that improve patient outcomes while supporting more efficient care delivery. As healthcare systems increasingly focus on value-based care, demand for technologies that reduce complications, shorten recovery times, and improve patient experience is expected to remain strong.
American Industrial Partners believes operational improvements will play an important role in unlocking Avanos’ future growth potential. The investment firm has built its reputation by working closely with management teams to strengthen manufacturing operations, optimize supply chains, improve productivity, and support strategic expansion initiatives.
Speaking after the transaction closed, AIP Partner Joel Rotroff said the company views Avanos as an attractive platform for continued growth within the medical technology industry. He emphasized that combining Avanos’ market position with AIP’s operational expertise creates opportunities to accelerate the company’s long-term development strategy.
For Avanos, the acquisition also provides access to additional financial and operational resources that could support investment across research, product development, manufacturing capabilities, and commercial expansion.
Private Ownership Creates New Opportunities for Innovation and Commercial Expansion
The AIP Avanos acquisition also highlights the broader trend of private investment reshaping the medical technology sector. Healthcare companies with established product portfolios are increasingly becoming acquisition targets as investors seek businesses capable of generating long-term value through innovation and operational improvements rather than rapid cost reductions alone.
Avanos Chief Executive Officer Dave Pacitti described the transaction as the beginning of a new phase for the company, noting that the business enters private ownership with strong commercial momentum and an active innovation pipeline. He stated that AIP’s operational capabilities and investment approach are expected to help accelerate initiatives that have already been developed internally while providing the resources needed to pursue future growth opportunities.
Industry analysts have observed that medical technology companies often benefit from private ownership because management teams are able to focus on strategic priorities such as product innovation, geographic expansion, manufacturing modernization, and clinical development without the immediate pressures associated with public market reporting.
For AIP, the acquisition expands an already significant investment portfolio. The firm has completed more than 145 platform and add-on acquisitions throughout its history and oversees portfolio companies generating approximately $32 billion in combined annual revenue while employing more than 74,000 people worldwide. Its investment strategy has consistently focused on engineering-led businesses with opportunities for operational transformation and sustainable value creation.
The completion of the AIP Avanos acquisition reinforces growing investor confidence in the resilience of the medical technology market. As healthcare providers continue investing in advanced medical devices that improve clinical outcomes and operational efficiency, companies with differentiated technologies remain attractive acquisition targets for long-term investors.
With the transaction now complete, market attention is likely to shift toward Avanos’ execution under private ownership. Stakeholders will closely watch how the company advances its product development roadmap, strengthens its global commercial presence, and leverages AIP’s operational capabilities to expand its position within the competitive medical technology landscape.
The successful completion of the AIP Avanos acquisition therefore represents more than the conclusion of a corporate transaction. It establishes the foundation for a new phase of strategic investment, operational growth, and innovation that could shape the company’s direction for years to come.
